In the originally published article there was an error in Table 1. The reduction in monthly migraine days over 12 weeks versus placebo with quarterly fremanezumab was incorrectly given as “-0.6”; this should read “-3.7”.
Share this Article
Related Content In Headache Disorders
External Trigeminal Nerve Stimulation as a Non-pharmacological Option for the Prevention and Acute Treatment of Migraine
touchREVIEWS in Neurology. 2022;18(1):Online ahead of journal publication.
Migraine is a common and disabling condition with substantial health and socioeconomic implications. Approximately 1.04 billion people worldwide have migraine disease.1 The condition disproportionately affects women, with 19% of women versus 10% of men reporting a history of migraine.1 Migraine is the second leading cause of years lived with disability across both genders and all ages; further, […]
Dim the Lights: A Narrative Review of Photophobia in Migraine
touchREVIEWS in Neurology 2022;18(1):Online ahead of journal publication
It cannot be seen, cannot be felt, cannot be heard, cannot be smelt. It lies behind stars and under hills, and empty holes it fills. It comes first and follows after, ends life, kills laughter. The Hobbit. JRR Tolkien ‘Darkness’ was the answer to Gollum’s riddle to get out of the tunnel in The Hobbit.1 Darkness is the […]
Zolmitriptan for Early Onset of Action in Acute Migraine Attacks
touchREVIEWS in Neurology. 2021;17(2):74–6 DOI: https://doi.org/10.17925/USN.2021.17.2.74
Migraine is a neurologic disease characterized by recurrent attacks of head pain and symptoms such as nausea, photophobia and phonophobia, which last hours to days.1 Attacks themselves can be disabling, and due to the often unpredictable and unavoidable nature of the attacks, the disease itself accounts for substantial disability.2 In fact, migraine affects 12% of the global […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!